Celldex Therapeutics Ownership
| CLDX Stock | USD 27.02 0.80 3.05% |
Shares in Circulation | First Issued 1985-09-30 | Previous Quarter 66 M | Current Value 66.3 M | Avarage Shares Outstanding 7.4 M | Quarterly Volatility 15.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Celldex |
Celldex Stock Ownership Analysis
About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Celldex Therapeutics was currently reported as 11.85. The company recorded a loss per share of 2.58. Celldex Therapeutics last dividend was issued on the 11th of February 2019. The entity had 1:15 split on the 11th of February 2019. Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey. Celldex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 132 people. For more info on Celldex Therapeutics please contact the company at 908 200 7500 or go to https://www.celldex.com.Besides selling stocks to institutional investors, Celldex Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Celldex Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Celldex Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Celldex Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Celldex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Celldex Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Celldex Therapeutics backward and forwards among themselves. Celldex Therapeutics' institutional investor refers to the entity that pools money to purchase Celldex Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.7 M | Geode Capital Management, Llc | 2024-06-30 | 1.5 M | Commodore Capital Lp | 2024-06-30 | 1.4 M | Rock Springs Capital Management Lp | 2024-06-30 | 1.4 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.4 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.4 M | Jennison Associates Llc | 2024-09-30 | 1.3 M | Novo A/s | 2024-09-30 | 963.7 K | Goldman Sachs Group Inc | 2024-06-30 | 874.2 K | Wellington Management Company Llp | 2024-06-30 | 8.1 M | Fmr Inc | 2024-09-30 | 6 M |
Celldex Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celldex Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celldex Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Celldex Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Celldex Therapeutics Outstanding Bonds
Celldex Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Celldex Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Celldex bonds can be classified according to their maturity, which is the date when Celldex Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| CELULOSA ARAUCO Y Corp BondUS151191BD46 | View | |
| CELARA 3875 02 NOV 27 Corp BondUS151191BB89 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| US15118JAA34 Corp BondUS15118JAA34 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Celldex Therapeutics Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 25th of April 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.